LATS2 and chronic myelogenous leukemia, BCR-ABL1 positive: The effect of LATS on the tumorigenic properties of CML cells was further validated by our shRNA knockdown of the LATS1 and LATS2 genes in K562 cells, which showed an effect similar to TRULI treatment.